Abstract
Numerous genetic variants have been studied in the context of antiplatelet responsiveness, particularly for aspirin and clopidogrel. The majority of these variants have failed to demonstrate any measurable level of clinical validity with the exception of the CYP2C19*2 allele. Several studies have identified a link between CYP2C19*2 carriers and decreased clopidogrel responsiveness as assessed by platelet reactivity testing and clinical outcomes. The FDA boxed warning and strong evidence of the CYP2C19*2 allele provide a compelling indication to alter treatment when genotype information is available. However, several questions remain and universal genotyping cannot be recommended at this time without further studies that establish the clinical utility of genomic testing for clopidogrel.
Keywords: Antiplatelet agents, aspirin, clopidogrel, clopidogrel variability, CYP2C19, pharmacogenomics, polymorphism, prasugrel, allele, antithrombotic
Current Drug Targets
Title: Progress of Antiplatelet Pharmacogenomics
Volume: 12 Issue: 12
Author(s): Julie H. Oestreich
Affiliation:
Keywords: Antiplatelet agents, aspirin, clopidogrel, clopidogrel variability, CYP2C19, pharmacogenomics, polymorphism, prasugrel, allele, antithrombotic
Abstract: Numerous genetic variants have been studied in the context of antiplatelet responsiveness, particularly for aspirin and clopidogrel. The majority of these variants have failed to demonstrate any measurable level of clinical validity with the exception of the CYP2C19*2 allele. Several studies have identified a link between CYP2C19*2 carriers and decreased clopidogrel responsiveness as assessed by platelet reactivity testing and clinical outcomes. The FDA boxed warning and strong evidence of the CYP2C19*2 allele provide a compelling indication to alter treatment when genotype information is available. However, several questions remain and universal genotyping cannot be recommended at this time without further studies that establish the clinical utility of genomic testing for clopidogrel.
Export Options
About this article
Cite this article as:
H. Oestreich Julie, Progress of Antiplatelet Pharmacogenomics, Current Drug Targets 2011; 12 (12) . https://dx.doi.org/10.2174/138945011797635849
DOI https://dx.doi.org/10.2174/138945011797635849 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Selective Serotonin Reuptake Inhibitors for Premature Ejaculation: Review of Erectile and Ejaculatory Side Effects
Current Drug Safety The MAPK / JNK Signalling Pathway Offers Potential Therapeutic Targets for the Prevention of Acquired Deafness
Current Drug Targets - CNS & Neurological Disorders Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery Heart Failure And Type 2 Diabetes Mellitus: Neurohumoral, HistologicalAnd Molecular Interconnections
Current Cardiology Reviews The Role of High-density Lipoprotein in Oral and Dental Diseases
Current Medicinal Chemistry Hemodynamic Monitoring in the Acute Management of Pediatric Heart Failure
Current Cardiology Reviews Biodistribution of Radiolabeled [ 3 H] CMT-3 in Rats
Current Medicinal Chemistry 1,8-Naphthyridine Derivatives: A Privileged Scaffold for Versatile Biological Activities
Mini-Reviews in Medicinal Chemistry Thymosin β4 Protein Therapy for Cardiac Repair
Current Pharmaceutical Design Metabolic Functions of Myostatin and GDF11
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of Hyphenated Chromatography-Mass Spectrometry Techniques in Exploratory Drug Metabolism and Pharmacokinetics
Current Pharmaceutical Design Pathophysiologic Mechanisms of Tobacco Smoke Producing Atherosclerosis
Current Cardiology Reviews Dyslipidemias and Microcirculation
Current Pharmaceutical Design IL-1 as a target in inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in Synthesis of PAR Ligands as Therapeutic Strategy for Inflammatory Diseases
Mini-Reviews in Medicinal Chemistry Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases
Current Pharmaceutical Design SGLT2 Inhibitors and Diabetic Kidney Disease: Targeting Multiple andInterrelated Signaling Pathways for Renal Protection
Current Molecular Pharmacology Evaluation of the Atherogenic Effect of Covid-19 Pneumonia on Coronary andCarotid Arteries in Patients who Recovered from the Disease
Current Medical Imaging Impact of the Renin-Angiotensin-Aldosterone-System on Cardiovascular and Renal Complications in Diabetes Mellitus
Current Vascular Pharmacology Controversies on HDL: Should it be a Target Biomarker in Patients with Lipid Disorders?
Current Vascular Pharmacology